CA-ESRI
Esri , the global leader in location intelligence, today announced that the Emirates Real Estate Solutions (ERES) land development and land market services and Khatib & Alami (K&A) will use Esri's ArcGIS system to geoenable ERES solutions and service offerings to the international land development and real estate market.
By incorporating Esri's capabilities for field collection, spatial analytics, and mapping into the ERES infrastructure and solutions, ERES can now provide real-time data like valuable locations, sales assessments, and rent indexes. This allows investors and regulators to establish equitable valuation and property taxation through embedded dashboards and maps that provide an instant view of the real estate development market from any device, anywhere, and anytime.
In the early 2000s, the government of Dubai initiated a financial transition to become service and tourism oriented, allowing foreign investors to buy freehold properties, helping the city become a center for investment. To encourage and support this, ERES developed a suite of solutions and in the process gained expertise in providing technology and services to ensure secure and efficient real estate investments.
"ERES is pleased to have inked this agreement with Esri and K&A, both of whom are prime leaders in cadastre solutions and the land survey domain," said Khalifa Al Suwaidi, ERES CEO and board member. "ERES' vision [for] unique and present intellectual property products and experiences [is] to . . . grow and bring all solutions to the bigger market . . . of real estate."
An urban and regional planning, architectural, and engineering consulting company, as well as an Esri platinum partner, K&A brings decades of successful deployment throughout the Middle East, Central Asia, and Africa. The firm is also specifically qualified to help governments and other real estate entities deploy the ERES platform and build local capacity to maintain, operate, and expand its solutions over time.
"We are pleased to collaborate with Esri and ERES in this vital initiative, which provides stakeholders in the UAE's real estate industry with innovative IT solutions, adding more efficiency and transparency to the marketplace," said Faisal Alami, K&A executive vice president. "Our vast experience as a leading geospatial systems integrator will help us bring new levels of visibility and understanding for real estate investors, which will support their decision-making and ultimately drive confidence and growth in the sector."
"Digital transformation is happening around the world at unprecedented rates, and geospatial data is now foundational for most businesses and governments," said Sohail Elabd, director of Esri Middle East and Africa. "The ERES geospatial platform is a unique project that brings geospatial technology to real estate on a tremendous scale for the first time in the Middle East and Africa."
This collaboration around a geographic information system (GIS)-based real estate solution will provide governments, investors, developers, real estate agents, and property owners with a unique and highly adaptable software infrastructure, which can help drive and sustain economies centered around the land market.
To learn more about the new ERES platform, visit eres.ae .
About K&A
Khatib & Alami (K&A) is an international multidisciplinary consultancy composed of architects, engineers, planners, technologists and other project specialists. With 6,000 people in more than 30 locations, K&A has vast experience working at the forefront of fast changing urban environments, with a deep understanding of delivering complex major projects within agreed time frames and budgets.
Since launching its Geospatial Systems Integration division in 1988, K&A has become among the leaders in its field, with a 200-strong team of GIS experts. K&A helps government and private sector clients make sense of the vast quantities of information and data available to them, providing insight, enabling better decision-making, creating efficiencies, and improving customer experiences. As an Esri platinum partner, K&A continuously provides innovative smart solutions that address business challenges and exceed customers' expectations. For more information visit www.khatibalami.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005747/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom